

March 3, 2014

---

# CymaBay Therapeutics Appoints Pol Boudes M.D. to Position of Chief Medical Officer

NEWARK, CA -- (Marketwired) -- 03/03/14 -- CymaBay Therapeutics, Inc. (OTCQB: CYMA), a biopharmaceutical company developing breakthrough therapies addressing unmet medical needs in metabolic diseases, today announced that Dr. Pol Boudes has joined the company as Chief Medical Officer. Dr. Boudes brings extensive clinical development experience to CymaBay, including expertise in all phases of clinical trial design and execution.

Prior to joining CymaBay, Dr. Boudes was Chief Medical Officer at Amicus Therapeutics. From 2004 to 2009, Dr. Boudes was with Berlex Laboratories (which merged with Bayer HealthCare Pharmaceuticals in 2006) where he held the position of Vice President, Global Clinical Development, Women's Health Care US. From 1990 to 2004, he held positions of increasing responsibility with Wyeth-Ayerst Research both in Philadelphia, PA and in Europe, with Hoffmann-La Roche, and with Pasteur-Merieux Serums & Vaccins. Dr. Boudes received his M.D. from the University of Aix-Marseilles, France. He completed his internship and residency in Marseilles and in Paris, France and was an Assistant Professor of Medicine at the University of Paris. He is specialized in Endocrinology and Metabolic Diseases, Internal Medicine, and Geriatric diseases.

"Pol is a great addition to our management team," said President and Chief Executive Officer Harold Van Wart, Ph.D. "His extensive industry experience in drug development, and in clinical trial design and execution leading to the registration of multiple drugs in the U.S. and ex-U.S. will be invaluable to us. Moreover, Pol's demonstrated expertise in orphan indications will benefit CymaBay as it assesses the best indications to pursue for its pipeline projects."

## ***About CymaBay***

CymaBay Therapeutics is a clinical-stage biopharmaceutical company developing breakthrough therapies addressing unmet medical needs. Arhalofenate, the company's lead product candidate, possesses two therapeutic actions in a single drug. In gout patients, arhalofenate is intended to prevent painful attacks in joints while at the same time promoting excretion of uric acid by the kidney, thereby removing the root cause of this debilitating disease.

For additional information about CymaBay visit [www.cymabay.com](http://www.cymabay.com).

Contact:

Sujal Shah

CymaBay Therapeutics, Inc.

(510) 293-8800

[investors@cymabay.com](mailto:investors@cymabay.com)

Adam Cutler  
The Trout Group, LLC  
(646) 378-2936  
[CymaBay@troutgroup.com](mailto:CymaBay@troutgroup.com)

Source: CymaBay Therapeutics